Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Shionogi to Snap Up UMN Pharma to Bolster Vaccine Biz
Shionogi said on October 30 that it will launch a tender offer to acquire the entire stake in UMN Pharma, a vaccine developer based in the northern Japan prefecture of Akita, in a bid to step up its business in…
To read the full story
Related Article
- Shionogi Cuts Full-Year Guidance as Xofluza Sales Freefall
February 4, 2020
- UMN to Become Shionogi’s Subsidiary on Dec. 19
December 16, 2019
- Shionogi’s Half-Year Sales Slip 4.4% after Xofluza Milestone Gain
October 31, 2019
- Shionogi, UMN Pharma Conclude Capital Alliance; Tie Up in Infectious Disease Field
November 2, 2017
BUSINESS
- Senju, Novartis Ink Promotion Tie-Up for Eye Drug Beovu in Japan
February 4, 2026
- Datroway Accepted for US Review for 1st-Line TNBC: Daiichi Sankyo
February 4, 2026
- Veozah Hits Primary Goal in Japan PIII Study: Astellas
February 4, 2026
- Sawai Cedes to Merck in Januvia Row, Accepts Patent Scope
February 4, 2026
- Nippon Kayaku’s Avastin Biosimilar Share Hits 58%
February 3, 2026
Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…